Trial Profile
A randomized trial to evaluate the effectiveness of antiretroviral therapy plus HIV primary care versus HIV primary care alone to prevent the sexual transmission of HIV-1 in serodiscordant couples.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35 *
At a glance
- Drugs Atazanavir (Primary) ; Didanosine (Primary) ; Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine (Primary) ; Lamivudine/zidovudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nevirapine (Primary) ; Stavudine (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 Mar 2021 Results assessing pregnancy rates and clinical Outcome comparisons among women living with Hiv, presented at the 28th Conference on Retroviruses and Opportunistic Infections
- 26 Jul 2017 Results (n=253) of secondary analysis to understand the impact ART drugs on pregnancy and birth outcomes among women from this trial and ACTG A5175 and ACTG A5208 trial, were presented at the 9th International AIDS Society Conference on HIV Science.
- 27 Jul 2012 Results presented at the 19th International AIDS Conference.